Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q3 2025 value amounting to $99.5 million.

  • Tarsus Pharmaceuticals' Change in Acquisitions & Divestments rose 30620.53% to $99.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $305.2 million, marking a year-over-year increase of 45102.1%. This contributed to the annual value of $73.0 million for FY2024, which is 5823.08% down from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Change in Acquisitions & Divestments is $99.5 million, which was up 30620.53% from $79.0 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Change in Acquisitions & Divestments peaked at $99.5 million during Q3 2025, and registered a low of $2.5 million during Q1 2024.
  • For the 4-year period, Tarsus Pharmaceuticals' Change in Acquisitions & Divestments averaged around $43.6 million, with its median value being $37.9 million (2023).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Change in Acquisitions & Divestments crashed by 9379.67% in 2024, and later skyrocketed by 354872.0% in 2025.
  • Tarsus Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $5.3 million in 2022, then skyrocketed by 235.84% to $17.8 million in 2023, then soared by 98.68% to $35.5 million in 2024, then skyrocketed by 180.56% to $99.5 million in 2025.
  • Its Change in Acquisitions & Divestments was $99.5 million in Q3 2025, compared to $79.0 million in Q2 2025 and $91.2 million in Q1 2025.